Sanofi | SNY - Interest Expense On Debt



Sanofi reported 62M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.


Interest Expense On Debt Change Date
AbbVie USD 700M 90M Mar/2025
Amgen USD 694M 29M Jun/2025
AstraZeneca 303M 126M Jun/2025
Bristol-Myers Squibb USD 485M 9M Jun/2025
Canopy Growth CAD 9.74M 7.03M Jun/2025
Corcept Therapeutics 6M 6M Jun/2024
Drreddys Laboratories INR 817M 60M Dec/2024
Eli Lilly USD 249M 5.3M Jun/2025
Galapagos EUR 780K 49.34M Mar/2025
Genmab DKK 9M 4M Jun/2025
GlaxoSmithKline 184M 22M Jun/2025
Glaxosmithkline 184M 5.95M Jun/2025
J&J USD 128M 9M Mar/2025
Merck USD 305M 8M Jun/2025
Novartis USD 289M 19M Jun/2025
Novartis USD 289M 14M Jun/2025
Pacira USD 3.82M 110K Jun/2025
Perrigo 39.6M 600K Jun/2025
Pfizer USD 654M 0 Jun/2025
Prestige Brands USD 10.2M 275K Jun/2025
Roche Holding CHF 311.5M 1000K Dec/2024
Sanofi 148M 65M Jun/2025
Sanofi 62M 4.11M Jun/2025
Supernus Pharmaceuticals USD 0 0 Dec/2024
UCB 108M 16M Dec/2024
Zoetis USD 53M 1000K Jun/2025